Clinical trials: Major Depression
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Symptoms, Major Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of…
- Conditions
- Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology
- Trial name
- NCT05461599
- Testing
- SparkRx Mobile App
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Limbix Health, Inc.
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Major Depressive Disorder
Self-guided Treatment for Depression
This study will examine the efficacy and safety of a self-guided digital therapeutic app for the adjunct treatment of Major Depressive Disorder compared to a control app in adolescents and adults.
- Trial name
- NCT06028984
- Testing
- Intervention app, Control app
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Big Health Inc.
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depression
Major Depressive Disorder (MDD)
The purpose of this study is to assess the effectiveness of systematic screening for depression in high-risk patient participants in everyday clinical practice.
- Trial name
- NCT01662817
- Testing
- Intervention, Control
- Where
- Spain
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).
- Trial name
- NCT00413023
- Testing
- GW679769
- Where
- 39 sites in Argentina, Belgium and 9 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an…
- Trial name
- NCT00878748
- Testing
- Effexor XR, Effexor XR discontinue
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy of quetiapine fumarate sustained release (Seroquel SR™) in combination with an antidepressant versus an antidepressant alone in patients with Major Depressive Disorder.
- Trial name
- ONYX (NCT00351910)
- Testing
- Quetiapine, Amitriptyline, Bupropion
- Where
- 72 sites in Australia, Belgium and 10 more
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
Depressive Disorder
A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo…
- Trial name
- NCT00336713
- Testing
- Saredutant (SR48968C)
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Sanofi
Major Depressive Disorder
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder…
- Trial name
- NCT06223880
- Testing
- AXS-05, Bupropion
- Where
- 40 sites in United States
- Volunteers
- 350 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder.
- Trial name
- NCT00863798
- Testing
- Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg
- Where
- 24 sites in United States
- Volunteers
- 682 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Episodes, Bipolar I Depression
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
A clinical trial to study the efficacy and safety of an investigational drug in people with major depressive episodes associated with with Bipolar I disorder (bipolar I depression) Participants in the study will either receive…
- Trial name
- NCT05169710
- Testing
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg
- Where
- 89 sites in United States, Bulgaria and 4 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depressive Disorder, Major
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
- Trial name
- NCT00733980
- Testing
- GSK561679
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
- Trial name
- NCT07772531
- Testing
- BMS-986511
- Where
- 27 sites in United States, Czechia
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb